New Zealand markets open in 3 hours

Zhejiang Garden Biopharmaceutical Co.,Ltd. (300401.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
12.20+0.22 (+1.84%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 6.61B
Enterprise value 6.80B
Trailing P/E 32.11
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.71
Price/book (mrq)2.20
Enterprise value/revenue 6.13
Enterprise value/EBITDA 22.85

Trading information

Stock price history

Beta (5Y monthly) 0.03
52-week change 38.93%
S&P500 52-week change 326.24%
52-week high 314.37
52-week low 37.58
50-day moving average 311.46
200-day moving average 310.80

Share statistics

Avg vol (3-month) 322.06M
Avg vol (10-day) 317.85M
Shares outstanding 5541.7M
Implied shares outstanding 6541.7M
Float 8347.67M
% held by insiders 136.76%
% held by institutions 15.92%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.07
Forward annual dividend yield 40.58%
Trailing annual dividend rate 30.07
Trailing annual dividend yield 30.59%
5-year average dividend yield 40.36
Payout ratio 436.84%
Dividend date 3N/A
Ex-dividend date 415 May 2024
Last split factor 22.5:1
Last split date 304 May 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 20.94%
Operating margin (ttm)22.95%

Management effectiveness

Return on assets (ttm)2.07%
Return on equity (ttm)7.80%

Income statement

Revenue (ttm)1.11B
Revenue per share (ttm)2.05
Quarterly revenue growth (yoy)4.10%
Gross profit (ttm)N/A
EBITDA 332.98M
Net income avi to common (ttm)231.97M
Diluted EPS (ttm)0.38
Quarterly earnings growth (yoy)76.40%

Balance sheet

Total cash (mrq)1.72B
Total cash per share (mrq)3.2
Total debt (mrq)1.57B
Total debt/equity (mrq)52.39%
Current ratio (mrq)1.91
Book value per share (mrq)5.59

Cash flow statement

Operating cash flow (ttm)131.3M
Levered free cash flow (ttm)-153.52M